Mona Celander
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mona Celander has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Amulya Krishna Shetty
Alligator Bioscience AB, Lund, Sweden
26 shared publications - Anette Sundstedt
Alligator Bioscience AB, Lund, Sweden
26 shared publications - Anna Säll
Alligator Bioscience AB, Lund, Sweden
26 shared publications - Anneli Nilsson
Alligator Bioscience AB, Lund, Sweden
26 shared publications - Dietmar Weilguny
Alligator Bioscience AB, Lund, Sweden
26 shared publications - Hampus Andersson
Alligator Bioscience AB, Lund, Sweden
26 shared publications
Latest Publications
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S18 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Supplementary Figure S18. ATOR-4066 and PD-1 inhibitor enhances activation of exhausted T cells in MLR assay with MoDCs, individual donor pairs.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S18 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Supplementary Figure S18. ATOR-4066 and PD-1 inhibitor enhances activation of exhausted T cells in MLR assay with MoDCs, individual donor pairs.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Despite recent progress within the field of immuno-oncology, immune suppression in the tumor microenvironment, defective antigen presentation, and low levels of tumor-specific T cells are key limitations of current cancer immunotherapies. CD40-targeting immunotherapies hold promise for addressing these limitations across solid tumors. In this study, we describe ATOR-4066, a bispecific antibody that targets CD40 and CEACAM5, developed using the Neo-X-Prime platform. ATOR-4066 showed potent CEACAM5-dependent activation in vitro, with an ability to activate intratumoral immune cells from patient-derived material. In vivo, ATOR-4066 induced superior antitumor activity compared with a CD40 mAb in MC38–carcinoembryonic antigen tumors and cured mice with well-established tumors with heterogeneous CEACAM5 expression. Using RNA sequencing, flow cytometry, and cytokine analysis, we showed that ATOR-4066 promoted immune cell trafficking to tumors and activated both myeloid cells and T cells within the tumor microenvironment, with limited immune activation in the periphery. ATOR-4066 initially induced a T cell–independent antitumor response, yet we found that a functional T-cell response was critical for long-term tumor control and immunity directed to tumor antigens other than CEACAM5. Finally, we demonstrated that ATOR-4066 synergized with PD-1 blockade in vitro. In conclusion, these data provide mechanistic evidence for the proposed mode of action and support further development of ATOR-4066 in CEACAM5-expressing cancers.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Despite recent progress within the field of immuno-oncology, immune suppression in the tumor microenvironment, defective antigen presentation, and low levels of tumor-specific T cells are key limitations of current cancer immunotherapies. CD40-targeting immunotherapies hold promise for addressing these limitations across solid tumors. In this study, we describe ATOR-4066, a bispecific antibody that targets CD40 and CEACAM5, developed using the Neo-X-Prime platform. ATOR-4066 showed potent CEACAM5-dependent activation in vitro, with an ability to activate intratumoral immune cells from patient-derived material. In vivo, ATOR-4066 induced superior antitumor activity compared with a CD40 mAb in MC38–carcinoembryonic antigen tumors and cured mice with well-established tumors with heterogeneous CEACAM5 expression. Using RNA sequencing, flow cytometry, and cytokine analysis, we showed that ATOR-4066 promoted immune cell trafficking to tumors and activated both myeloid cells and T cells within the tumor microenvironment, with limited immune activation in the periphery. ATOR-4066 initially induced a T cell–independent antitumor response, yet we found that a functional T-cell response was critical for long-term tumor control and immunity directed to tumor antigens other than CEACAM5. Finally, we demonstrated that ATOR-4066 synergized with PD-1 blockade in vitro. In conclusion, these data provide mechanistic evidence for the proposed mode of action and support further development of ATOR-4066 in CEACAM5-expressing cancers.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Supplementary Figure S12. Representative flow of myeloid cells.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Supplementary Figure S12. Representative flow of myeloid cells.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Supplementary Figure S9 Individual tumor growth curves of mice treated with 100ug CD40 mAb, 167 ug ATOR-4066 or vehicle.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Supplementary Figure S9 Individual tumor growth curves of mice treated with 100ug CD40 mAb, 167 ug ATOR-4066 or vehicle.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Supplementary Figure S10. Representative images of immunohistochemistry analysis (performed by Truly Labs, Lund, Sweden). Antibody accumulation in MC38-CEA tumors as quantified in figure 2. Equimolar doses of mAb and bsAb (100 µg and 167 µg, respectively). Treatment day 10 and 13 after inoculation, analysis at day 14.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Supplementary Figure S10. Representative images of immunohistochemistry analysis (performed by Truly Labs, Lund, Sweden). Antibody accumulation in MC38-CEA tumors as quantified in figure 2. Equimolar doses of mAb and bsAb (100 µg and 167 µg, respectively). Treatment day 10 and 13 after inoculation, analysis at day 14.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Binding to human CD40 receptors transfected into cells, where domains, or part of domains (module A and B of domain 1) has been replaced with the corresponding murine CD40 sequence as described by Ellmark and colleagues [32].
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Binding to human CD40 receptors transfected into cells, where domains, or part of domains (module A and B of domain 1) has been replaced with the corresponding murine CD40 sequence as described by Ellmark and colleagues [32].
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Supplementary Figure S15. A, Cytokine levels in liver lysates of mice inoculated with MC38-CEA tumors and treated twice (day 6 and 10) with either ATOR-4066 (40, 167 or 360 µg/dose) or vehicle were measured by Luminex 11-plex cytokine panel 24 hours after last treatment. Except for IL-6 that was seen to be increased at 167 µg of ATOR-4066, no differences in any of the 11 measured cytokines were seen. B, AST levels in plasma from mice treated twice (day 6 and 10) with ATOR-4066 (10, 40, 167 or 360 µg/dose), CD40 mAb (100 µg/dose) or vehicle was measure by ELISA 24 hours after last treatment. CD40 mAb, but not ATOR-4066, increased plasma levels of AST.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Supplementary Figure S15. A, Cytokine levels in liver lysates of mice inoculated with MC38-CEA tumors and treated twice (day 6 and 10) with either ATOR-4066 (40, 167 or 360 µg/dose) or vehicle were measured by Luminex 11-plex cytokine panel 24 hours after last treatment. Except for IL-6 that was seen to be increased at 167 µg of ATOR-4066, no differences in any of the 11 measured cytokines were seen. B, AST levels in plasma from mice treated twice (day 6 and 10) with ATOR-4066 (10, 40, 167 or 360 µg/dose), CD40 mAb (100 µg/dose) or vehicle was measure by ELISA 24 hours after last treatment. CD40 mAb, but not ATOR-4066, increased plasma levels of AST.